About Agenus Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://agenusbio.com/
Frequently Asked Questions
What is the 52-week range for AGEN?
The 52-week high is $10.31 and the 52-week low is $2.71.
What is the P/E ratio for AGEN?
The Price to Earnings (P/E) ratio is 4.13.
What is the dividend yield for AGEN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 76.63%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 69.34%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 24.02.
Analyst Recommendation Trends
Wall Street analyst consensus for AGEN over the last few months:
Latest AGEN News
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
LEXINGTON, Mass., October 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.
Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with
Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock Soaring - But Caution Advised
Agenus Inc. has surged >195% YTD, driven by optimism around its BOT/BAL combo therapy for MSS colon cancer. Read more on AGEN stock here.
Agenus: Hot Times As It Trudges Towards BOT/BAL Submission
Agenus (AGEN) bets on BOT/BAL immunotherapy ahead of the ROBBIN Phase 3 MSS colon cancer trial.
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
Rodman & Renshaw Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $19
Rodman & Renshaw analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $19.
Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing
Agenus now carries an updated implied fair value of about US$26.33 per share, up from US$19.50, which reflects a change of roughly 35% in the price target used in this analysis. Recent Street commentary links these higher targets to the botensilimab plus balstilimab program in microsatellite stable colorectal cancer and to fresh capital that affects how investors think about financing risk. Read on to see how this evolving narrative around Agenus could matter for your own view of the...
Chardan Capital Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $40
Chardan Capital analyst Andreas Argyrides initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $40.
Agenus Inc. (AGEN) Shareholder/Analyst Call - Slideshow
2026-09-11. The following slide deck was published by Agenus Inc.
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass., September 10, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-10 | ARMEN GARO H | +1,971,500 | - | - |
| 2026-08-05 | Marcucci Marco Tullio | +7,500 | - | - |
| 2026-08-05 | HARRISON THOMAS L | +50,000 | - | - |
| 2026-08-05 | Corvese Brian | +100,000 | - | - |
| 2026-08-05 | Wright Timothy | +50,000 | - | - |
| 2026-08-05 | O'Day Steven J | +100,000 | - | - |
| 2026-08-05 | Hirsch Susan B | +50,000 | - | - |
| 2026-08-05 | Buell Jennifer | +200,000 | - | - |
| 2026-07-10 | ARMEN GARO H | +4,852 | $3.35 | $16,254 |
| 2026-07-01 | HARRISON THOMAS L | +8,547 | $3.583 | $30,624 |
| 2026-07-01 | Wright Timothy | +2,268 | - | - |
| 2026-06-12 | ARMEN GARO H | +4,925 | $3.3 | $16,253 |
| 2026-05-29 | ARMEN GARO H | +4,644 | $3.5 | $16,254 |
| 2026-05-15 | ARMEN GARO H | +4,540 | $3.58 | $16,253 |
| 2026-05-01 | ARMEN GARO H | +4,233 | $3.84 | $16,255 |
| 2026-04-24 | Hirsch Susan B | +105,000 | - | - |
| 2026-04-24 | Buell Jennifer | +5,000 | - | - |
| 2026-04-24 | Buell Jennifer | +300,000 | - | - |
| 2026-04-24 | O'Day Steven J | +95,333 | - | - |
| 2026-04-24 | O'Day Steven J | +70,000 | - | - |
| 2026-04-24 | HARRISON THOMAS L | +122,500 | - | - |
| 2026-04-24 | Wright Timothy | +105,000 | - | - |
| 2026-04-24 | Charette Austin | +17,619 | - | - |
| 2026-04-24 | Charette Austin | +5,000 | - | - |
| 2026-04-24 | ARMEN GARO H | +137,550 | - | - |
| 2026-04-24 | ARMEN GARO H | +27,750 | - | - |
| 2026-04-24 | ARMEN GARO H | +1,000,000 | - | - |
| 2026-04-24 | Corvese Brian | +210,000 | - | - |
| 2026-04-17 | ARMEN GARO H | +3,403 | $4.79 | $16,300 |
| 2026-04-03 | ARMEN GARO H | +4,629 | $3.33 | $15,415 |
| 2026-04-01 | HARRISON THOMAS L | +9,228 | $3.319 | $30,628 |
| 2026-04-01 | Wright Timothy | +2,448 | - | - |
| 2026-03-20 | ARMEN GARO H | +3,983 | $3.71 | $14,777 |
| 2026-03-06 | ARMEN GARO H | +4,994 | $2.96 | $14,782 |
| 2026-02-20 | ARMEN GARO H | +4,829 | $3.06 | $14,777 |
| 2026-02-06 | ARMEN GARO H | +5,027 | $2.94 | $14,779 |
| 2026-01-23 | ARMEN GARO H | +4,562 | $3.24 | $14,781 |
| 2026-01-09 | ARMEN GARO H | +3,780 | $3.91 | $14,780 |
| 2026-01-02 | HARRISON THOMAS L | +7,691 | $3.982 | $30,626 |
| 2026-01-02 | Wright Timothy | +2,041 | - | - |
| 2025-12-26 | ARMEN GARO H | +4,942 | $3.31 | $16,358 |
| 2025-12-12 | ARMEN GARO H | +4,316 | $3.79 | $16,358 |
| 2025-11-28 | ARMEN GARO H | +3,587 | $4.56 | $16,357 |
| 2025-11-14 | ARMEN GARO H | +3,769 | $4.34 | $16,357 |
| 2025-10-31 | ARMEN GARO H | +4,120 | $3.97 | $16,356 |
| 2025-10-17 | ARMEN GARO H | +4,216 | $3.88 | $16,358 |
| 2025-10-03 | ARMEN GARO H | +3,951 | $4.14 | $16,357 |